Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
doi: 10.1038/s41572-025-00630-5
Ezetimibe, bempedoic acid, PCSK9 mAbs, and inclisiran expand the therapeutic armamentarium
By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial
US$ 28.04
US$ 29.65
US$ 20.72
US$ 23.00
